P
Peter J. Barnes
Researcher at National Institutes of Health
Publications - 1554
Citations - 177909
Peter J. Barnes is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Asthma & COPD. The author has an hindex of 194, co-authored 1530 publications receiving 166618 citations. Previous affiliations of Peter J. Barnes include University of Nebraska Medical Center & Novartis.
Papers
More filters
Journal ArticleDOI
Effect of theophylline and adenosine on eosinophil function.
TL;DR: The results indicate that therapeutic concentrations of theophylline may potentiate eosinophil activation in vivo by competing with circulating adenosine for eosInophil A2-receptors, which would be consistent with the lack of effect of the Flower on bronchial hyperresponsiveness, which may be related to eos inophilic inflammation.
Journal ArticleDOI
Nortriptyline Reverses Corticosteroid Insensitivity by Inhibition of Phosphoinositide-3-Kinase-δ
TL;DR: Nortriptyline restores corticosteroid sensitivity induced by oxidative stress via direct inhibition of PI3Kδ and is a potential treatment for corticosticosteroid-insensitive diseases such as COPD and severe asthma.
Journal ArticleDOI
Nitric oxide synthase activity is elevated in inflammatory lung disease in humans
Maria G. Belvisi,Peter J. Barnes,S W Larkin,Magdi H. Yacoub,Samad Tadjkarimi,Timothy J. Williams,Jane A. Mitchell +6 more
TL;DR: Higher levels of NO synthase activity were found in samples from patients with inflammatory lung disease (mild asthma, cystic fibrosis, obliterative bronchiolitis after lung transplantation) compared to samples from healthy donors, suggesting a modulatory role for nitric oxide in lung inflammation.
Journal ArticleDOI
Cytokine-directed therapies for asthma ☆ ☆☆
TL;DR: The evaluation of cytokines with anti-inflammatory effects in human beings, including IL-10, IL-12, and IFN-gamma, is at a preliminary stage, but so far results have not been encouraging.
Journal ArticleDOI
Validation of the anti-inflammatory properties of small-molecule IκB kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle
Matthew C. Catley,Maria B. Sukkar,K. Fan Chung,Bruce Jaffee,Sha-Mei Liao,Anthony J. Coyle,El-Bdaoui Haddad,Peter J. Barnes,Robert Newton +8 more
TL;DR: Adenoviral overexpression is used to demonstrate NF-κB and IKK2 dependence of key inflammatory genes and suggest that IKK inhibitors may be of considerable benefit in inflammatory airways diseases, particularly in COPD or severe asthma, in which corticosteroids are ineffective.